Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma gptkb:head_and_neck_squamous_cell_carcinoma melanoma Hodgkin lymphoma renal cell carcinoma |
| gptkbp:contraindication |
severe autoimmune disease
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
gptkb:Bristol-Myers_Squibb |
| gptkbp:discoveredIn |
2010s
|
| gptkbp:enhance |
T-cell immune response
|
| gptkbp:example |
gptkb:pembrolizumab
gptkb:cemiplimab gptkb:nivolumab |
| https://www.w3.org/2000/01/rdf-schema#label |
PD-1 inhibitors
|
| gptkbp:mechanismOfAction |
block PD-1 pathway
|
| gptkbp:regulates |
immune response
|
| gptkbp:sideEffect |
diarrhea
fatigue rash immune-related adverse events |
| gptkbp:target |
PD-1 protein
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:PD-L1_expression
|
| gptkbp:bfsLayer |
6
|